Skip to main content
Erschienen in: Annals of Surgical Oncology 6/2010

01.06.2010 | Urologic Oncology

Cervical Lymph Node Dissection for Metastatic Testicular Cancer

verfasst von: M. G. van Vledder, MD, J. A. van der Hage, MD, W. J. Kirkels, MD, J. W. Oosterhuis, MD, C. Verhoef, MD, J. H. W. de Wilt

Erschienen in: Annals of Surgical Oncology | Ausgabe 6/2010

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Despite high response rates to systemic chemotherapy, 30% of patients with advanced stage testicular carcinoma will have extra-retroperitoneal residual masses that require resection. Most often, these are located in the lungs and mediastinum and neck. Limited data are available concerning the incidence, surgical management, and follow-up of neck metastasis arising from a testicular primary tumor.

Methods

We retrospectively reviewed all 665 patients who were referred to a tertiary referral center with the diagnosis of testicular cancer from January 1997 to June 2009 for the presence of cervical metastases. Patients who underwent concomitant surgical therapy were identified and analyzed. Clinical and pathological data were collected from patient records, including radiology and pathology reports. Furthermore, data on primary treatment strategy, chemotherapeutic regimens, timing of surgical procedures, complications, disease recurrence, and follow-up were collected.

Results

Twenty-six patients (4%) had cervical lymph node metastasis. The majority (n = 19) had multiple ERP sites. Nine patients (35%) underwent selective neck dissection: in six patients, this was indicated because of residual masses after chemotherapy, and in three patients, cervical masses represented a late and distant relapse of previously treated disease. Viable cancer cells were present in the resected specimen only in these three patients. Seven patients are currently without evidence of disease. Two patients died of disseminated disease.

Conclusions

Cervical lymph node metastases originating from testicular cancer are rare but are more commonly observed in patients with advanced stage disease. Selective neck dissection can be safely performed both after chemotherapy and in the case of recurrent disease.
Literatur
1.
Zurück zum Zitat See WA, et al. Incidence and management of testicular carcinoma metastatic to the neck. J Urol. 1996;155(2):590–2.CrossRefPubMed See WA, et al. Incidence and management of testicular carcinoma metastatic to the neck. J Urol. 1996;155(2):590–2.CrossRefPubMed
2.
Zurück zum Zitat Carver BS, Sheinfeld J. Management of post-chemotherapy extra-retroperitoneal residual masses. World J Urol. 2009;27:489–92. Carver BS, Sheinfeld J. Management of post-chemotherapy extra-retroperitoneal residual masses. World J Urol. 2009;27:489–92.
3.
Zurück zum Zitat Motzer RJ, et al. Teratoma with malignant transformation: diverse malignant histologies arising in men with germ cell tumors. J Urol. 1998;159(1):133–8.CrossRefPubMed Motzer RJ, et al. Teratoma with malignant transformation: diverse malignant histologies arising in men with germ cell tumors. J Urol. 1998;159(1):133–8.CrossRefPubMed
4.
Zurück zum Zitat McGuire MS, et al. The role of thoracotomy in managing postchemotherapy residual thoracic masses in patients with nonseminomatous germ cell tumours. BJU Int. 2003;91(6):469–73.CrossRefPubMed McGuire MS, et al. The role of thoracotomy in managing postchemotherapy residual thoracic masses in patients with nonseminomatous germ cell tumours. BJU Int. 2003;91(6):469–73.CrossRefPubMed
5.
Zurück zum Zitat Weisberger EC, McBride LC. Modified neck dissection for metastatic nonseminomatous testicular carcinoma. Laryngoscope. 1999;109(8):1241–4.CrossRefPubMed Weisberger EC, McBride LC. Modified neck dissection for metastatic nonseminomatous testicular carcinoma. Laryngoscope. 1999;109(8):1241–4.CrossRefPubMed
6.
Zurück zum Zitat Lee JT, Calcaterra TC. Testicular carcinoma metastatic to the neck. Am J Otolaryngol. 1998;19(5):325–9.CrossRefPubMed Lee JT, Calcaterra TC. Testicular carcinoma metastatic to the neck. Am J Otolaryngol. 1998;19(5):325–9.CrossRefPubMed
7.
Zurück zum Zitat Zeph RD, et al. Modified neck dissection for metastatic testicular carcinoma. Arch Otolaryngol. 1985;111(10):667–72.PubMed Zeph RD, et al. Modified neck dissection for metastatic testicular carcinoma. Arch Otolaryngol. 1985;111(10):667–72.PubMed
8.
Zurück zum Zitat Krege S, et al. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. Eur Urol. 2008;53(3):478–96.CrossRefPubMed Krege S, et al. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. Eur Urol. 2008;53(3):478–96.CrossRefPubMed
9.
Zurück zum Zitat Krege S, et al. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II. Eur Urol. 2008;53(3):497–513.CrossRefPubMed Krege S, et al. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II. Eur Urol. 2008;53(3):497–513.CrossRefPubMed
10.
Zurück zum Zitat Fizazi K, et al. Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy: results from an international study group. J Clin Oncol. 2001;19(10):2647–57.PubMed Fizazi K, et al. Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy: results from an international study group. J Clin Oncol. 2001;19(10):2647–57.PubMed
11.
Zurück zum Zitat Hartmann JT, et al. Comparison of histological results from the resection of residual masses at different sites after chemotherapy for metastatic non-seminomatous germ cell tumours. Eur J Cancer. 1997;33(6):843–7.CrossRefPubMed Hartmann JT, et al. Comparison of histological results from the resection of residual masses at different sites after chemotherapy for metastatic non-seminomatous germ cell tumours. Eur J Cancer. 1997;33(6):843–7.CrossRefPubMed
12.
Zurück zum Zitat Steyerberg EW, et al. Residual pulmonary masses after chemotherapy for metastatic nonseminomatous germ cell tumor. Prediction of histology. ReHiT Study Group. Cancer. 1997;79(2):345–55.CrossRefPubMed Steyerberg EW, et al. Residual pulmonary masses after chemotherapy for metastatic nonseminomatous germ cell tumor. Prediction of histology. ReHiT Study Group. Cancer. 1997;79(2):345–55.CrossRefPubMed
13.
Zurück zum Zitat Oechsle K, et al. [18F]Fluorodeoxyglucose positron emission tomography in nonseminomatous germ cell tumors after chemotherapy: the German multicenter positron emission tomography study group. J Clin Oncol. 2008;26(36):5930–5.CrossRefPubMed Oechsle K, et al. [18F]Fluorodeoxyglucose positron emission tomography in nonseminomatous germ cell tumors after chemotherapy: the German multicenter positron emission tomography study group. J Clin Oncol. 2008;26(36):5930–5.CrossRefPubMed
14.
Zurück zum Zitat Cappiello J, et al. Shoulder disability after different selective neck dissections (levels II–IV versus levels II–V): a comparative study. Laryngoscope. 2005;115(2):259–63.CrossRefPubMed Cappiello J, et al. Shoulder disability after different selective neck dissections (levels II–IV versus levels II–V): a comparative study. Laryngoscope. 2005;115(2):259–63.CrossRefPubMed
Metadaten
Titel
Cervical Lymph Node Dissection for Metastatic Testicular Cancer
verfasst von
M. G. van Vledder, MD
J. A. van der Hage, MD
W. J. Kirkels, MD
J. W. Oosterhuis, MD
C. Verhoef, MD
J. H. W. de Wilt
Publikationsdatum
01.06.2010
Verlag
Springer-Verlag
Erschienen in
Annals of Surgical Oncology / Ausgabe 6/2010
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-010-1036-x

Weitere Artikel der Ausgabe 6/2010

Annals of Surgical Oncology 6/2010 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.